TW202207933A - 包含tno155及那紮替尼之藥物組合 - Google Patents

包含tno155及那紮替尼之藥物組合 Download PDF

Info

Publication number
TW202207933A
TW202207933A TW110116377A TW110116377A TW202207933A TW 202207933 A TW202207933 A TW 202207933A TW 110116377 A TW110116377 A TW 110116377A TW 110116377 A TW110116377 A TW 110116377A TW 202207933 A TW202207933 A TW 202207933A
Authority
TW
Taiwan
Prior art keywords
day
cancer
egfr
amino
pharmaceutically acceptable
Prior art date
Application number
TW110116377A
Other languages
English (en)
Chinese (zh)
Inventor
蘇珊 穆迪
郝淮湘
劉晨
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202207933A publication Critical patent/TW202207933A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110116377A 2020-05-08 2021-05-06 包含tno155及那紮替尼之藥物組合 TW202207933A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US63/021,772 2020-05-08
US202063117388P 2020-11-23 2020-11-23
US63/117,388 2020-11-23

Publications (1)

Publication Number Publication Date
TW202207933A true TW202207933A (zh) 2022-03-01

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110116377A TW202207933A (zh) 2020-05-08 2021-05-06 包含tno155及那紮替尼之藥物組合

Country Status (12)

Country Link
US (1) US20230172928A1 (https=)
EP (1) EP4146217A1 (https=)
JP (1) JP2023524789A (https=)
KR (1) KR20230008719A (https=)
CN (1) CN115397421A (https=)
AU (1) AU2021267213B2 (https=)
BR (1) BR112022022305A2 (https=)
CA (1) CA3179994A1 (https=)
IL (1) IL297043A (https=)
MX (1) MX2022013867A (https=)
TW (1) TW202207933A (https=)
WO (1) WO2021224867A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867718B (zh) 2018-09-29 2025-03-04 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
IL305106B2 (en) 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
US12441737B2 (en) 2020-07-08 2025-10-14 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of SHP2
US20250127782A1 (en) 2021-09-08 2025-04-24 Amgen Inc. Methods of treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3048340A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
IL305106B2 (en) * 2018-09-29 2025-08-01 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2

Also Published As

Publication number Publication date
BR112022022305A2 (pt) 2022-12-20
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30
AU2021267213B2 (en) 2023-11-30
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
JP2023524789A (ja) 2023-06-13
EP4146217A1 (en) 2023-03-15
US20230172928A1 (en) 2023-06-08
IL297043A (en) 2022-12-01
WO2021224867A1 (en) 2021-11-11
KR20230008719A (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
US11298362B2 (en) Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer
TW202207933A (zh) 包含tno155及那紮替尼之藥物組合
EP3288383A1 (en) Methods of treating cancer
CA3121930A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer